UPDATE : Friday, July 10, 2020
HOME Pharma
Albis most prescribed ranitidine drug with carcinogen risk
  • By Kwak Sung-sun
  • Published 2019.10.07 11:23
  • Updated 2019.10.07 15:51
  • comments 0

Physicians have prescribed Albis Tab. the most among ranitidine-containing stomach medicines, which authorities are soon to ban for good due to the detection of N-Nitrosodimethylamine (NDMA), a possibly cancer-causing chemical

Rep. Jung Choun-sook of the ruling Democratic Party on Sunday released the list of the top 10 ranitidine drugs that have been most prescribed in the past two years and a half, based on data from the Health Insurance Review and Assessment Service.

The total prescriptions of ranitidine drugs numbered 48 million in 2017, 53.6 million in 2018, and 29.1 million in the first half of 2019. During the two and a half years, prescriptions of ranitidine medicines have totaled 130.7 million.

The 10 most prescribed ranitidine drugs are Daewoong Pharmaceutical’s Albis Tab with 17.2 million prescriptions, Daewoong Bio’s Rabisu Tab. with 6.5 million, Ildong Pharmaceutical’s Curan Tab. with 5.3 million, Ildong’s Curan Tab. 75 mg with 4.8 million, Hutecs Korea Pharmaceutical’s Rubis Tab. with 4.2 million, Mothers Pharm’s Racetin M Tab. with 3.7 million, RP Bio’s Gazete Tab. with 3.4 million, Huon’s ELBUS Tab. with 3.4 million, Nex Pharm Korea’s Nexina Tab. with 3.3 million, and Hanmi Pharmaceutical’s Ranivic S Tab. with 2.4 million.

“Only several drugs such as Curan are known to have contained raw materials with carcinogen risk, but there are many other medicines that have been prescribed as much,” Jung said. “Patients taking stomach drugs need to recheck their medication.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Kwak Sung-sun
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top